Improved NEXICART-2 data; runway extends

Immix Biopharma has announced an update from its ongoing US-based NEXICART-2 study testing NXC-201 in relapsed/refractory amyloid light chain amyloidosis (r/r ALA), alongside a sizeable equity financing to support continued development activities. The latest clinical update showed that all four measurable residual disease (MRD)-negative patients previously reported at ASH 2025 have now converted to complete response (CR), increasing the CR rate to 95% (19/20 patients) in the first 20 evaluable participants. Importantly, all CRs were reached within one year following dosing and no relapses have been observed to date among patients who achieved CR. We view this as an encouraging progression from the prior dataset, which showed a 75% CR rat...